Investing News NetworkYour trusted source for investing success
Helium Evolution
Integrated Cyber Solutions
Purepoint Uranium
Soma Gold Corp.
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Immune Design Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
Immune Design (Nasdaq:IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today reported financial results and a corporate update for the fourth quarter and full year ended December 31, 2017. As quoted in the press release: “In 2017, we demonstrated the clinical activity of our two lead product candidates that turn “cold” tumors “hot,” …
Immune Design (Nasdaq:IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today reported financial results and a corporate update for the fourth quarter and full year ended December 31, 2017.
As quoted in the press release:
“In 2017, we demonstrated the clinical activity of our two lead product candidates that turn “cold” tumors “hot,” and enhanced our balance sheet,” said Carlos Paya, M.D., Ph.D., President and Chief Executive Officer of Immune Design. “In 2018, our goal is to continue to create value and advance these novel therapies toward registration paths for patients with sarcoma and follicular lymphoma, while also setting the stage for potential expansion into multiple larger patient tumor populations.”
Outlook Reports
Featured Genetics Investing Stocks
Browse Companies
MARKETS
COMMODITIES
Commodities | |||
---|---|---|---|
Gold | 2014.44 | +12.07 | |
Silver | 24.65 | +0.31 | |
Copper | 3.80 | 0.00 | |
Oil | 75.16 | +0.30 | |
Heating Oil | 2.76 | 0.00 | |
Natural Gas | 2.79 | 0.00 |
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.